Tripterygium wilfordii Hook F versus conventional synthetic disease-modifying anti-rheumatic drugs as monotherapy for rheumatoid arthritis: a systematic review and network meta-analysis
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1472-6882
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Tripterygium wilfordii Hook F versus conventional synthetic disease-modifying anti-rheumatic drugs as monotherapy for rheumatoid arthritis: a systematic review and network meta-analysis ; volume:16 ; number:1 ; day:13 ; month:7 ; year:2016 ; pages:1-8 ; date:12.2016
BMC complementary and alternative medicine ; 16, Heft 1 (13.7.2016), 1-8, 12.2016
- Creator
-
Wang, Hai-Long
- Contributor
-
Jiang, Quan
Feng, Xing-Hua
Zhang, Hua-Dong
Ge, Lin
Luo, Cheng-Gui
Gong, Xun
Li, Bo
SpringerLink (Online service)
- DOI
-
10.1186/s12906-016-1194-x
- URN
-
urn:nbn:de:101:1-2018071223140776256923
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:37 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Wang, Hai-Long
- Jiang, Quan
- Feng, Xing-Hua
- Zhang, Hua-Dong
- Ge, Lin
- Luo, Cheng-Gui
- Gong, Xun
- Li, Bo
- SpringerLink (Online service)
Other Objects (12)
The sequence of disease-modifying anti-rheumatic drugs: pathways to and predictors of tocilizumab monotherapy
Utilizing biologic disease-modifying anti-rheumatic treatment sequences to subphenotype rheumatoid arthritis
Abatacept monotherapy compared with abatacept plus disease-modifying anti-rheumatic drugs in rheumatoid arthritis patients: data from the ORA registry
Use of Anti-Tumor Necrosis Factor Therapy: A Retrospective Study of Monotherapy and Adherence to Combination Therapy with Non-Biologic Disease-Modifying Anti-Rheumatic Drugs
Effect of disease-modifying anti-rheumatic drugs on bone structure and strength in psoriatic arthritis patients
Association between obesity and remission in rheumatoid arthritis patients treated with disease-modifying anti-rheumatic drugs
Effect of disease-modifying anti-rheumatic drugs on bone structure and strength in psoriatic arthritis patients
Cost-utility analysis of de-escalating biological disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis
Variability in response to anti-rheumatic drugs
Risk factors for bone loss in patients with rheumatoid arthritis treated with biologic disease-modifying anti-rheumatic drugs
Real-World Drug Survival of Biologics and Targeted Synthetic Disease-Modifying Anti-rheumatic Drugs Among Patients with Psoriatic Arthritis
Immunogenicity of Sarilumab Monotherapy in Patients with Rheumatoid Arthritis Who Were Inadequate Responders or Intolerant to Disease-Modifying Antirheumatic Drugs
The sequence of disease-modifying anti-rheumatic drugs: pathways to and predictors of tocilizumab monotherapy
Utilizing biologic disease-modifying anti-rheumatic treatment sequences to subphenotype rheumatoid arthritis
Abatacept monotherapy compared with abatacept plus disease-modifying anti-rheumatic drugs in rheumatoid arthritis patients: data from the ORA registry
Use of Anti-Tumor Necrosis Factor Therapy: A Retrospective Study of Monotherapy and Adherence to Combination Therapy with Non-Biologic Disease-Modifying Anti-Rheumatic Drugs
Effect of disease-modifying anti-rheumatic drugs on bone structure and strength in psoriatic arthritis patients
Association between obesity and remission in rheumatoid arthritis patients treated with disease-modifying anti-rheumatic drugs
Effect of disease-modifying anti-rheumatic drugs on bone structure and strength in psoriatic arthritis patients
Cost-utility analysis of de-escalating biological disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis
Variability in response to anti-rheumatic drugs
Risk factors for bone loss in patients with rheumatoid arthritis treated with biologic disease-modifying anti-rheumatic drugs
Real-World Drug Survival of Biologics and Targeted Synthetic Disease-Modifying Anti-rheumatic Drugs Among Patients with Psoriatic Arthritis
Immunogenicity of Sarilumab Monotherapy in Patients with Rheumatoid Arthritis Who Were Inadequate Responders or Intolerant to Disease-Modifying Antirheumatic Drugs
The sequence of disease-modifying anti-rheumatic drugs: pathways to and predictors of tocilizumab monotherapy
Utilizing biologic disease-modifying anti-rheumatic treatment sequences to subphenotype rheumatoid arthritis
Abatacept monotherapy compared with abatacept plus disease-modifying anti-rheumatic drugs in rheumatoid arthritis patients: data from the ORA registry
Use of Anti-Tumor Necrosis Factor Therapy: A Retrospective Study of Monotherapy and Adherence to Combination Therapy with Non-Biologic Disease-Modifying Anti-Rheumatic Drugs
Effect of disease-modifying anti-rheumatic drugs on bone structure and strength in psoriatic arthritis patients
Association between obesity and remission in rheumatoid arthritis patients treated with disease-modifying anti-rheumatic drugs
Effect of disease-modifying anti-rheumatic drugs on bone structure and strength in psoriatic arthritis patients
Cost-utility analysis of de-escalating biological disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis
Variability in response to anti-rheumatic drugs
Risk factors for bone loss in patients with rheumatoid arthritis treated with biologic disease-modifying anti-rheumatic drugs
Real-World Drug Survival of Biologics and Targeted Synthetic Disease-Modifying Anti-rheumatic Drugs Among Patients with Psoriatic Arthritis